Category Archives: Biotech

Global Biosimilars Market to Soar to $24 Billion by 2019

Frost & Sullivan: Strong Pipeline of Monoclonal Antibodies (mAbs) Biosimilars in the US and Europe Lends Impetus to Global Market The market is expected to soar from $1.2 billion of 2013 to $24 billion in 2019 LONDON – 29th January 2014 – The imminent entry of several companies, including big pharma, small biotech and generic […]
Also posted in Europe, Global, Strategy | Tagged , , | 1 Comment

Time for Russia to Get Serious about Biopharma

Back in 1980, the biotech industry did not exist. There was little difference between the means of production in Western markets and the socialist planned economies embodied by Russia – medicines, still a low-tech purchase, played a modest role in the delivery of health care in both sectors. What happened in the ensuing decades has […]
Also posted in Emerging Markets, Europe, Global, Strategy | Tagged , , , | 1 Comment

Momenta CEO Rebuffs Teva's Copaxone Defense

Momenta Pharmaceuticals’ CEO Craig Wheeler said comments made by Teva leadership about a “purported” generic of Copaxone are “kind of humorous.” Teva’s Copaxone, a multiple sclerosis drug that earns nearly $4 billion a year, is approaching patent expiry – and possible generic competition – on May 24. Assuming FDA approves a generic version of Copaxone, […]
Also posted in FDA, IP, leadership, Legal, People, pricing, R&D, Regulatory, Strategy | Tagged , , , , , , , | Leave a comment

J.P. Morgan: Pharma's Agenda for 2014

Presenters at the 32nd annual J.P. Morgan Healthcare Conference talked up value-based pricing, emerging market strategies, complex generics and new technology, from bedside devices and genetic sequencers to first-in-class mechanisms of action. Company executives honed in on their chosen therapeutic areas and made the case for aggressive spending in R&D to bring the next generation […]
Also posted in Corporate Responsibility, Deals, Emerging Markets, Europe, Events, FDA, Gene therapy, Global, IP, leadership, Legal, Manufacturing, Market Access, Orphan Drugs, People, pricing, R&D, Regulatory, Safety, Sales, Strategy, Technology | Tagged , , , , , , , , , , , , , , , , , | Leave a comment

Prove It! Top Line Thoughts on Trends That Will Shape the Industry in 2014

Top Line Thoughts on 2014:  Prove It! Ten days in and the New Year already seems old.  Yet members of our Pharm Exec Editorial Advisory Board are still eager to share their top of line predictions on trends that will shape the industry’s business and reputational assets – forward and backward – over the busy […]
Also posted in Strategy | Tagged , , , , | Leave a comment
  • Categories

  • Meta